Two dose levels of ifosfamide in malignant mesothelioma

Icli F., Karaoguz H., Hasturk S., Kurt B., AKBULUT H., Dincol D., ...Daha Fazla

LUNG CANCER, cilt.15, sa.2, ss.207-213, 1996 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 2
  • Basım Tarihi: 1996
  • Doi Numarası: 10.1016/0169-5002(96)00584-3
  • Dergi Adı: LUNG CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.207-213
  • Anahtar Kelimeler: malignant mesothelioma, dose-response, ifosfamide, PLEURAL MESOTHELIOMA, ONCOLOGY-GROUP, MESNA
  • Ankara Üniversitesi Adresli: Evet

Özet

Thirty-one consecutive patients with histologically proven and symptomatic malignant mesothelioma were treated with two dose levels of ifosfamide. The first group of 15 patients were given 2.3 g/m(2)/day for 5 days (group A) and the following 16 patients were treated with 1.2 g/m(2)/day for 5 days of ifosfamide (group B). Treatment cycles were repeated every 3 weeks. While the partial response rate (PR) in group A was 38.5%, it was only 6.25% in group B (P > 0.05). The 95% confidence interval for the difference in PR rates was 3.3-61.2%. The overall survival (OAS) of groups A and B were similar (8 months and 9 months, respectively). Higher Grade 3-4 myelotoxicity was observed in group A when compared to group B (30.8% vs. 18.7%; P > 0.05). In conclusion, a favourable response rate could be achieved in malignant mesothelioma with high dose ifosfamide at the cost of increased toxicity.